Drugs / CTX120
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04244656 | Jan 2020 → Jan 2024 | plasma cell myeloma | CRISPR Therapeutics AG | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CTX120 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04244656 ↗ |
| Modality | Cell therapy | “CTX120 B-cell maturation antigen (BCMA)-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components.” NCT04244656 ↗ |
| Route | Intravenous | “Administered by IV infusion” NCT04244656 ↗ |